Smiths Group PLC Appoint new CEO for Smiths Medical

Smiths Group Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Smiths Group plc (LON: SMIN) has today announced the appointment of JehanZeb Noor as Chief Executive Officer of Smiths Medical. JehanZeb will be part of Smiths Group’s Executive Committee and report to Andy Reynolds Smith, CEO of Smiths Group plc.

JehanZeb will take up the role on 1 July 2019 and will oversee the separation of Smiths Medical, which is expected to be completed during the first half of CY2020.

JehanZeb joins from Amcor Flexibles Inc., where he led the Healthcare North America business and Global Sales for Medical. Amcor is a specialist producer of sterile packaging for the global medical device and pharmaceuticals industries. During his three-year tenure at Amcor he drove a significant improvement in margin and revenue growth and led the integration of a major acquisition. Prior to joining Amcor, JehanZeb was a Partner at McKinsey & Company where he served for 9 years. He has a deep understanding of the MedTech supply chain, operations, distribution, product development and regulatory approval processes. JehanZeb holds a BSc in Finance and a BSc and MSc in Mechanical Engineering from the Massachusetts Institute of Technology.

Andy Reynolds Smith, Chief Executive of Smiths Group plc, commented:

“I look forward to working with JehanZeb as we continue building a strong, sustainable future for Smiths Medical and progress the separation of the business from Smiths Group. I am confident that JehanZeb’s intimate understanding of the MedTech industry combined with his strong track record of effective leadership, delivering growth and enhanced performance will make him a great success.”

JehanZeb Noor, Smiths Medical Chief Executive Officer Designate, commented:

“Smiths Medical is an industry leader, offering high quality specialised medical devices across the globe with significant investment in new products. The company will begin an exciting new chapter when it separates from the wider Group and I’m looking forward to the opportunity to join the team and lead the journey ahead to achieve our full potential, while serving a life saving mission.”

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Smiths Group plc (LON:SMIN) reports robust Q1 2024 growth, boosting FY2025 guidance and resuming an increased share buyback program.
    Smiths Group Plc (LON:SMIN) reports strong FY2024 results with 5.4% organic revenue growth, 16.8% profit margin, new acquisitions, and strategic initiatives.
    Smiths Group plc (LON:SMIN) reports Q3 trading statement with 7.7% organic revenue growth. FY2024 guidance of 4-6% organic growth reaffirmed.
    Smiths Group PLC (LON:SMIN) reports strong half-year results with organic revenue growth and double-digit order growth, underpinning future growth and performance improvements.

      Search

      Search